

**BioCell**

**Cytokine and Chemokine  
Neutralizing Antibodies**

$\alpha$ -IL-4 ·  $\alpha$ -IL-17A ·  $\alpha$ -IFN $\gamma$  ·  $\alpha$ -TNF $\alpha$  ·  $\alpha$ -TGFB & more!

EXPLORE

## The Journal of Immunology

RESEARCH ARTICLE | JULY 15 2003

### Inhibitory Effects of Surfactant Protein A on Surfactant Phospholipid Hydrolysis by Secreted Phospholipases A<sub>2</sub><sup>1</sup> **FREE**

Sophie Chabot; ... et. al

*J Immunol* (2003) 171 (2): 995–1000.

<https://doi.org/10.4049/jimmunol.171.2.995>

#### Related Content

Secreted Phospholipase A<sub>2</sub> Group X Acts as an Adjuvant for Type 2 Inflammation, Leading to an Allergen-Specific Immune Response in the Lung

*J Immunol* (June,2020)

*Staphylococcus aureus* Adenosine Inhibits sPLA<sub>2</sub>-IIA-Mediated Host Killing in the Airways

*J Immunol* (June,2015)

High Bactericidal Efficiency of Type IIA Phospholipase A<sub>2</sub> against *Bacillus anthracis* and Inhibition of Its Secretion by the Lethal Toxin

*J Immunol* (July,2004)

# Inhibitory Effects of Surfactant Protein A on Surfactant Phospholipid Hydrolysis by Secreted Phospholipases A<sub>2</sub><sup>1</sup>

Sophie Chabot,\* Kamen Koumanov,<sup>†</sup> Gérard Lambeau,<sup>‡</sup> Michael H. Gelb,<sup>§</sup> Viviane Balloy,\* Michel Chignard,\* Jeffrey A. Whitsett,<sup>||</sup> and Lhousseine Touqui<sup>2\*</sup>

Hydrolysis of surfactant phospholipids by secreted phospholipases A<sub>2</sub> (sPLA<sub>2</sub>) contributes to surfactant dysfunction in acute respiratory distress syndrome. The present study demonstrates that sPLA<sub>2</sub>-IIA, sPLA<sub>2</sub>-V, and sPLA<sub>2</sub>-X efficiently hydrolyze surfactant phospholipids *in vitro*. In contrast, sPLA<sub>2</sub>-IIC, -IID, -IIE, and -IIF have no effect. Since purified surfactant protein A (SP-A) has been shown to inhibit sPLA<sub>2</sub>-IIA activity, we investigated the *in vitro* effect of SP-A on the other active sPLA<sub>2</sub> and the consequences of sPLA<sub>2</sub>-IIA inhibition by SP-A on surfactant phospholipid hydrolysis. SP-A inhibits sPLA<sub>2</sub>-X activity, but fails to interfere with that of sPLA<sub>2</sub>-V. Moreover, *in vitro* inhibition of sPLA<sub>2</sub>-IIA induces surfactant phospholipid hydrolysis correlates with the concentration of SP-A in surfactant. Intratracheal administration of sPLA<sub>2</sub>-IIA to mice causes hydrolysis of surfactant phosphatidylglycerol. Interestingly, such hydrolysis is significantly higher for SP-A gene-targeted mice, showing the *in vivo* inhibitory effect of SP-A on sPLA<sub>2</sub>-IIA activity. Administration of sPLA<sub>2</sub>-IIA also induces respiratory distress, which is more pronounced in SP-A gene-targeted mice than in wild-type mice. We conclude that SP-A inhibits sPLA<sub>2</sub> activity, which may play a protective role by maintaining surfactant integrity during lung injury. *The Journal of Immunology*, 2003, 171: 995–1000.

Acute respiratory distress syndrome (ARDS)<sup>3</sup> is a lung injury with a high mortality rate, characterized by an acute inflammatory response in the lung parenchyma associated with severe injury to the epithelial and endothelial barriers (1). One of the typical features of ARDS is a pronounced alteration of pulmonary surfactant that consists of a complex mixture of phospholipids (80–90%, w/w), neutral lipids (5–10%), and surfactant-specific proteins (5–10%) covering the alveolar surface. The major function of surfactant is to reduce the surface tension at the air-liquid interface of the alveolus. The destruction of surfactant results in loss of alveolar stability and severe deterioration of gas exchange, including alveolar collapse (2).

The role of secreted phospholipases A<sub>2</sub> (sPLA<sub>2</sub>s) in a variety of inflammatory diseases including ARDS is now clearly established (3, 4). The sPLA<sub>2</sub>s form a growing family of enzymes that catalyze the hydrolysis of the *sn*-2 ester bond of glycerophospholipids,

leading to the production of free fatty acids and lysophospholipids that serve as precursors for a variety of lipid-derived mediators involved in numerous biological activities (5, 6). To date, 10 different sPLA<sub>2</sub>s, referred to as groups IB, IIA, IIC, IID, IIE, IIF, III, V, X, and XII, have been characterized in mammals (7–12). Of particular interest, levels of sPLA<sub>2</sub> activity in bronchoalveolar lavage fluids (BALF) of patients with ARDS often correlate positively with the severity of the disease (13). However, the type of sPLA<sub>2</sub> involved in this disorder remains unclear. While sPLA<sub>2</sub>-IIA is able to efficiently hydrolyze surfactant phospholipids, thereby contributing to surfactant alteration as observed in ARDS (14), the involvement of the other cloned sPLA<sub>2</sub>s in this process is not yet defined, and their roles in ARDS lung disease remain uncertain. In this study we investigated the potential pathological contribution of the newly cloned sPLA<sub>2</sub>s in ARDS by analyzing their ability to hydrolyze surfactant phospholipids *in vitro*.

Alteration of surfactant phospholipids occurs very early during the development of ARDS. Therefore, the development of inhibitors of sPLA<sub>2</sub> preventing hydrolysis of surfactant phospholipids could represent an auspicious strategy for ARDS treatment. Indeed, despite recent advances in intensive care, the ARDS mortality rate still exceeds 40%, and there is no effective therapy apart from mechanical ventilation and other supportive measures (15). Interestingly, we previously showed that surfactant protein A (SP-A), which is the major surfactant-associated protein, inhibits the *in vitro* sPLA<sub>2</sub>-IIA activity through a direct protein-protein interaction (14). SP-A, which is a member of the C-type lectin superfamily and contains a COOH-terminal carbohydrate recognition domain (CRD) (16), plays an important role in pulmonary host defense and seems to inhibit inflammation following lung infection. Decreased SP-A levels in BALF are observed in patients with ARDS or at risk of developing ARDS (17–19). Thus, increased sPLA<sub>2</sub> activity associated with decreased SP-A might promote the hydrolysis of pulmonary surfactant observed in ARDS. The aim of the present investigation was also to examine the effects of SP-A on sPLA<sub>2</sub> activity *in vivo* and *in vitro*.

\*Unité de Défense Innée et Inflammation, Institut Pasteur, Institut National de la Santé et de la Recherche Médicale E 336, Paris, France; <sup>†</sup>Laboratoire de Biochimie, Unité de Recherche Associée Centre National de la Recherche Scientifique, Faculté de Médecine St. Antoine, Paris, France; <sup>‡</sup>Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Valbonne, France; <sup>§</sup>Departments of Chemistry and Biochemistry, University of Washington, Seattle, WA 98195; and <sup>||</sup>Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229

Received for publication January 13, 2003. Accepted for publication May 16, 2003.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported by grants from the Fondation pour la Recherche Médicale and the Ministère de la Recherche (to S.C.) and by National Institutes of Health Grant HL61646 (to J.A.W.) and HL36235 (to M.H.G.).

<sup>2</sup> Address correspondence and reprint requests to Dr. Lhousseine Touqui, Unité de Défense Innée et Inflammation, Institut National de la Santé et de la Recherche Médicale E 336, Institut Pasteur 25 rue du Dr. Roux, 75015 Paris, France. E-mail address: touqui@pasteur.fr

<sup>3</sup> Abbreviations used in this paper: ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; CRD, carbohydrate recognition domain; mGIIA sPLA<sub>2</sub>, group IIA recombinant mouse sPLA<sub>2</sub>; PC, phosphatidylcholine; Penh, enhanced pause; PG, phosphatidylglycerol; r-GP sPLA<sub>2</sub>-IIA, recombinant guinea pig sPLA<sub>2</sub>-IIA; SP-A, surfactant protein A; sPLA<sub>2</sub>, secreted phospholipase A<sub>2</sub>.

## Materials and Methods

### Animals and reagents

SP-A and GM-CSF knockout mice (SP-A<sup>-/-</sup> and GM-CSF<sup>-/-</sup>) were bred from the C57BL/6/129Sv F2 homozygous SP-A<sup>-/-</sup> and GM-CSF<sup>-/-</sup> mice as previously described (20, 21). Recombinant guinea pig sPLA<sub>2</sub>-IIA (r-GP sPLA<sub>2</sub>-IIA) was produced in our laboratory (22). The recombinant mouse sPLA<sub>2</sub>s were expressed and purified as described previously (9, 10, 23). The rabbit polyclonal anti-rat SP-A Ab was a gift from F. X. McCormack (University of Cincinnati, Cincinnati, OH). Fatty acid-free BSA, phosphatidylcholine (PC), and phosphatidylglycerol (PG) standards were purchased from Sigma-Aldrich (St. Louis, MO).

### Preparation of pulmonary surfactant

Animals were killed by i.p. administration of a lethal dose of sodium pentobarbital (Sanofi, Libourne, France). The trachea of mice was cannulated, and BALF collection was performed with a syringe by multiple cycles of instillation and aspiration with unitary 0.5 ml of saline to provide 4 ml of BALF for pulmonary surfactant isolation. Cell-free BALF was obtained after centrifugation (300 × *g* for 15 min), and pulmonary surfactant was isolated by centrifugation of cell-free BALF at 19,500 × *g* for 20 min.

### SDS-PAGE and immunoblot analysis

SDS-PAGE was performed according to the method described by Laemmli (24). Twelve percent gels were loaded with 5 μg of total pulmonary surfactant phospholipids from the different mice or, as a control, 1 μg of purified human SP-A in the presence of 5% (v/v) 2-ME. Proteins were transferred to nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) and probed with a rabbit polyclonal anti-SP-A Ab (1/50,000). Membrane was then probed with anti-rabbit IgG HRP-linked donkey Ab (1/2,500), washed, incubated with ECL detection reagent (Amersham Pharmacia Biotech, Little Chalfont, U.K.), and exposed to Kodak X-OMAT AR film (Kodak-Pathé, Paris, France). Protein standards (Bio-Rad, Hercules, CA) with molecular masses in the range of 6,500–175,000 were used.

### Incubation of sPLA<sub>2</sub>s with pulmonary surfactant

The sPLA<sub>2</sub> assay buffer contained 100 mM Tris, 150 mM NaCl, and 10 mM CaCl<sub>2</sub> (pH 8). Surfactant was suspended in this buffer and then submitted to ultrasonication for 5 min (150 W) using an MSE sonifier (Anemasse, France). After adjusting the phospholipid concentration to 2 mM, surfactant was incubated for 1 h at 37°C with the indicated sPLA<sub>2</sub>s in the presence of 0.1% BSA (final volume, 50 μl). To analyze the role of SP-A in SP-A<sup>+/+</sup> mice on fatty acid release by r-GP sPLA<sub>2</sub>-IIA, surfactant (2 mM phospholipid concentration) from SP-A<sup>+/+</sup> mice was preincubated with 5 μg of rabbit polyclonal anti-SP-A IgG or control rabbit IgG in a final volume of 50 μl overnight at room temperature. Surfactant was then incubated for 1 h at 37°C with 1 μg/ml r-GP sPLA<sub>2</sub>-IIA, and fatty acid release was analyzed as described below.

### Fatty acid analysis

Fatty acids were extracted by Dole's procedure modified by Tsujishita et al. (25) and methylated with diazomethane. The methylated derivatives were separated by gas chromatography on a capillary column containing Supelcowax 10 bonded phase (diameter, 0.32 mm; 30 m long; Supelco, Bellefonte, PA) on a gas chromatograph (5890 series II; Hewlett-Packard, Palo Alto, CA) and detected by mass spectrometry (10-10C; Nermag, Reuil, France).

### Analysis of pulmonary surfactant PC and PG

Lipids were extracted from isolated surfactant according to the method described by Bligh and Dyer (26). The separation of phospholipids was achieved by TLC using silica gel plates (Merck, St. Louis, MO) and a water/acetic acid/methanol/chloroform (65/45/3/1, v/v) solvent system. The surfactant PC and PG spots were localized by reference to corresponding standards and extracted from silica gel plates, and then their phosphorus contents were measured according to the method reported by Böttcher et al. (27).

### Administration of sPLA<sub>2</sub>-IIA to mice

SP-A<sup>-/-</sup> or SP-A<sup>+/+</sup> 7-wk-old male mice, weighing 25–30 g, were instilled through an intratracheal catheter with either 20 μg of group IIA recombinant mouse sPLA<sub>2</sub> (mGIIA sPLA<sub>2</sub>) dissolved in 50 μl of saline or the same volume of saline containing 5 mM CaCl<sub>2</sub>. One hour after treatment, mice were killed by an overdose of sodium pentobarbital. BALF was

collected, and pulmonary surfactant was isolated as described above. There were no significant differences in the total volume of saline infused into the lungs or in the volume recovered after the lavage procedure among any experimental groups. Mice were cared for in accordance with Pasteur Institute guidelines in compliance with the European animal welfare regulations.

### Measurement of respiratory functions

The respiratory function of freely moving mice was measured by barometric plethysmography using whole-body plethysmography (Buxco Electronics, USA) according to the manufacturer's instructions. In brief, anesthetized mice received intratracheal instillation of 20 μg of mGIIA sPLA<sub>2</sub> or equivalent volume of saline. Then, each animal was placed in a main chamber and pressure difference between this chamber and a reference chamber were measured with a differential pressure transducer connected to amplifier and recorded with BioSystem XA analyzer software (Buxco Electronics, Birmingham, U.K.). Enhanced pause (Penh) correlated very closely with pulmonary resistance and was calculated as follows: Penh = (Te - Tr)/Tr(PEP/PIP), where Te is the expiratory time (seconds), Tr is the relaxation time (time of the pressure decay to 36% of total box pressure at expiration), PEP is the peak expiratory pressure (milliliters per second), and PIP is the peak inspiratory pressure (milliliters per second).

### Statistical analysis

Results are expressed as the mean ± SEM for the indicated number of independently performed experiments. Comparisons between values were analyzed by Student's *t* test for unpaired data, and *p* < 0.05 was considered significant.


## Results

### *In vitro* hydrolysis by sPLA<sub>2</sub>-IIA of different natural surfactants containing various amounts of SP-A

We previously demonstrated the inhibitory effect of SP-A on sPLA<sub>2</sub>-IIA activity on synthetic PG substrates *in vitro* (14). To assess the relationship between SP-A and surfactant phospholipid hydrolysis by sPLA<sub>2</sub>-IIA, surfactants purified from wild-type mice, mice deficient in SP-A (SP-A<sup>-/-</sup> mice), or mice with increased alveolar SP-A (GM-CSF<sup>-/-</sup> mice) were used as substrates. In GM-CSF<sup>-/-</sup> mice, the increased SP-A content results from an alveolar accumulation of surfactant-associated proteins and phospholipids caused by impaired clearance by alveolar macrophages (28). The phospholipid concentrations of the different surfactants from SP-A<sup>+/+</sup>, SP-A<sup>-/-</sup>, and GM-CSF<sup>-/-</sup> mice were adjusted to 2 mM, and the concentration of SP-A was estimated by immunoblotting. As expected, SP-A was undetectable in the pulmonary surfactant from SP-A<sup>-/-</sup> mice, and its level was considerably increased in GM-CSF<sup>-/-</sup> mice compared with SP-A<sup>+/+</sup> mice (Fig. 1A).


The sPLA<sub>2</sub>-IIA activity was assessed by measuring the release of free fatty acids generated by surfactant phospholipid hydrolysis. As shown in Fig. 1B, the release of fatty acids by sPLA<sub>2</sub>-IIA was more pronounced in SP-A<sup>-/-</sup> mice than in SP-A<sup>+/+</sup> mice and was quasi-nonexistent in GM-CSF<sup>-/-</sup> mice. Previous studies have shown that neither the levels of surfactant proteins B, C, and D nor the sizes of alveolar phospholipid pool and their compositions are altered in SP-A<sup>-/-</sup> mice (20). Furthermore, SP-A<sup>-/-</sup> mice have no discernable abnormalities in surface activity or film stability even when lung injury is induced (20, 29). In GM-CSF<sup>-/-</sup> mice the surfactant phospholipid composition is also unaltered. Therefore, our results suggest that surfactant hydrolysis by sPLA<sub>2</sub>-IIA is inversely correlated to the levels of the surfactant-associated SP-A protein.

Although the targeted disruption of the murine SP-A gene does not affect the level and composition of surfactant phospholipid (20), we aimed to confirm whether the increase in fatty acid release by sPLA<sub>2</sub>-IIA was indeed due to the absence of SP-A rather than to any potential difference in the properties of surfactant of SP-A<sup>-/-</sup> mice. Thus, SP-A<sup>+/+</sup> surfactant was incubated overnight at



**FIGURE 1.** In vitro analysis of the hydrolysis by sPLA<sub>2</sub>-IIA of different natural surfactants containing various amounts of SP-A. *A*, Analysis by immunoblotting of surfactant-associated SP-A content in SP-A<sup>-/-</sup>, SP-A<sup>+/+</sup>, and GM-CSF<sup>-/-</sup> mice was performed after adjusting the phospholipid concentration to 2 mM. *B*, Fatty acid release was measured after 1-h incubation of sPLA<sub>2</sub>-IIA with 2 mM surfactant phospholipids from each mouse genotype. Results are expressed as the mean ± SEM obtained from three separate experiments, each being performed on a pool of surfactants collected from untreated mice. \*, *p* < 0.05, SP-A<sup>-/-</sup> mice vs SP-A<sup>+/+</sup> mice; #, *p* < 0.02, SP-A<sup>-/-</sup> mice vs GM-CSF<sup>-/-</sup> mice; §, *p* < 0.05, GM-CSF<sup>-/-</sup> mice vs SP-A<sup>+/+</sup> mice.

room temperature with a polyclonal anti-SP-A Ab to neutralize SP-A; sPLA<sub>2</sub>-IIA (1 µg/ml) was added for 1 h at 37°C, and the release of fatty acids was measured. Hydrolysis of surfactant phospholipids increased significantly when the surfactant was preincubated with the anti-SP-A Ab, confirming the inhibitory effect of SP-A on sPLA<sub>2</sub>-IIA activity (Fig. 2).



**FIGURE 2.** Neutralization by anti-SP-A Ab of the inhibitory effect of surfactant-associated SP-A on sPLA<sub>2</sub>-IIA activity. Surfactant from SP-A<sup>+/+</sup> mice (2 mM phospholipid concentration) was preincubated overnight at room temperature with anti-SP-A IgG or nonrelevant IgG; sPLA<sub>2</sub>-IIA (1 µg/ml) was then added for 1 h at 37°C, and the release of fatty acid was measured as indicated in *Materials and Methods*. Results are expressed as the mean ± SEM percentage of the control value (*n* = 3). \*, *p* < 0.05.


*Analysis of in vitro surfactant hydrolysis by various sPLA<sub>2</sub>s and effect of SP-A on sPLA<sub>2</sub> activity*

Recently, novel sPLA<sub>2</sub>s have been cloned, but their biological roles remain unknown (6). In this study we tested in vitro their ability to hydrolyze surfactant phospholipids using surfactant from SP-A<sup>-/-</sup> mice (Fig. 3). As previously found (14), sPLA<sub>2</sub>-IIA hydrolyzed surfactant phospholipids, and PG was the most preferred substrate for this enzyme. By contrast, the other type II sPLA<sub>2</sub>s, including IIC, IID, IIE, and IIF enzymes, were ineffective in hydrolysis. Both sPLA<sub>2</sub>-V and sPLA<sub>2</sub>-X hydrolyzed PC and PG. In summary, only sPLA<sub>2</sub>-IIA, sPLA<sub>2</sub>-V, and sPLA<sub>2</sub>-X hydrolyzed surfactant phospholipids.


We next investigated whether the presence of surfactant-associated SP-A interferes with PC and PG hydrolysis by comparing the activities of sPLA<sub>2</sub>-IIA, sPLA<sub>2</sub>-V, and sPLA<sub>2</sub>-X on surfactants from SP-A<sup>+/+</sup> and SP-A<sup>-/-</sup> mice. There was no significant difference in the hydrolysis of surfactant phospholipids from SP-A<sup>+/+</sup> and SP-A<sup>-/-</sup> mice by sPLA<sub>2</sub>-V (Fig. 4). In contrast, surfactant phospholipids from SP-A<sup>-/-</sup> mice were significantly more susceptible to hydrolysis by sPLA<sub>2</sub>-IIA and sPLA<sub>2</sub>-X than those from wild-type mice. The selective inhibition of sPLA<sub>2</sub> by SP-A (SP-A has no effect on sPLA<sub>2</sub>-V) and our previous observation of a direct binding between SP-A and sPLA<sub>2</sub>-IIA (14) strongly suggest that the effect of SP-A is due to a direct interaction with the enzyme and not to an alteration of phospholipid structure.

*In vivo effect of SP-A on surfactant hydrolysis by sPLA<sub>2</sub>-IIA*

Our above in vitro studies showed that sPLA<sub>2</sub>-IIA hydrolyzed surfactant phospholipids and that SP-A reduced susceptibility of surfactant to hydrolysis. However, sPLA<sub>2</sub>-IIA activity depends not only on the chemical nature of phospholipids, but also on their physical state (30). For instance, sPLA<sub>2</sub>-IIA is very active toward micellar lipids as in our in vitro assay (31). Because surfactant phospholipids form in vivo a monolayer film that may be differentially hydrolyzed by sPLA<sub>2</sub>-IIA, we examined the ability of sPLA<sub>2</sub>-IIA to hydrolyze surfactant phospholipids in vivo in SP-A<sup>-/-</sup> and SP-A<sup>+/+</sup> mice. In these experiments mGIIA sPLA<sub>2</sub> was instilled intratracheally into the lungs of SP-A<sup>-/-</sup> and SP-A<sup>+/+</sup> mice, and surfactant phospholipid hydrolysis was analyzed (Fig. 5). The ratio of PC/PG increased following the administration of sPLA<sub>2</sub>-IIA for SP-A<sup>-/-</sup> mice (Fig. 5A). While no change in PC



**FIGURE 3.** Analysis of in vitro surfactant hydrolysis by various sPLA<sub>2</sub>s. Surfactant (2 mM phospholipid concentration) from SP-A<sup>-/-</sup> mice was incubated for 1 h at 37°C with 1 µg/ml of the indicated sPLA<sub>2</sub>. After extraction of surfactant phospholipids, PC and PG were separated, and their amounts were measured as described in *Materials and Methods*. Data are expressed as a percentage of the control value and are the mean ± SEM of five independent experiments. \*, *p* < 0.03; \*\*, *p* < 0.006 (compared with control).



**FIGURE 4.** In vitro effect of surfactant-associated SP-A on the activities of sPLA<sub>2</sub>-IIA, sPLA<sub>2</sub>-V, and sPLA<sub>2</sub>-X. Following the protocol indicated in Fig. 3, surfactant (2 mM phospholipid concentration) from SP-A<sup>-/-</sup> or SP-A<sup>+/+</sup> mice was incubated for 1 h at 37°C with 1 μg/ml of the indicated sPLA<sub>2</sub>. Data are expressed as a percentage of the control value and are the mean ± SEM of five independent experiments. \*,  $p < 0.04$ , SP-A<sup>-/-</sup> mice vs SP-A<sup>+/+</sup> mice.

levels was observed following treatment with sPLA<sub>2</sub>-IIA, the PG content decreased significantly ( $13.5 \pm 4$  and  $38.4 \pm 7\%$  for SP-A<sup>+/+</sup> and SP-A<sup>-/-</sup> mice, respectively, compared with corresponding control animals that were treated with saline (Fig. 5B). These data indicate that sPLA<sub>2</sub>-IIA is able to efficiently hydrolyze PG under in vivo conditions. Secondly, we observed that the surfactant PG content decreased markedly in SP-A<sup>-/-</sup> mice compared with wild-type mice after administration of sPLA<sub>2</sub>-IIA. Collectively, these results demonstrate that surfactant-associated SP-A reduces the hydrolysis of surfactant PG by sPLA<sub>2</sub>-IIA in vivo.


#### *In vivo impairment of surfactant function by sPLA<sub>2</sub>-IIA and protective effect of SP-A*

To determine whether the decrease in PG leads to a defect of the surfactant function, we examined the effect of intratracheal administration of mGIIA sPLA<sub>2</sub> on respiratory functions expressed as an increase in Penh. The latter is an index of airway resistance resulting from lung injury. In sPLA<sub>2</sub>-IIA-treated mice, Penh increased after 3 h, peaked within ~4 h, and then returned to basal levels by 6 h (data not shown). The increase in lung resistance was significantly higher in SP-A<sup>-/-</sup> mice than in wild-type mice. These results suggest that PG hydrolysis by sPLA<sub>2</sub>-IIA leads to an impairment of lung surfactant function, and that SP-A is effective in protecting the lung from injury induced by mouse sPLA<sub>2</sub>-IIA.

## Discussion

Clinical studies have suggested that sPLA<sub>2</sub>s play a role in the pathogenesis of ARDS. Elevated levels of sPLA<sub>2</sub> activity have been reported in the BALF of patients; moreover, these levels correlated with the severity of the disease (13). However, the type of sPLA<sub>2</sub>s involved in ARDS has not been clearly established. Furthermore, the levels of SP-A, a surfactant protein with known in vitro inhibitory capacity of sPLA<sub>2</sub>-IIA activity, are considerably decreased in patients with ARDS. These considerations prompted us to investigate 1) the ability of newly cloned sPLA<sub>2</sub> family members to hydrolyze surfactant phospholipids, and 2) the potential effect of surfactant-associated SP-A on the activities of these various sPLA<sub>2</sub>s.

This study shows that the release of fatty acid, resulting from in vitro surfactant hydrolysis by sPLA<sub>2</sub>-IIA, is inversely correlated




**FIGURE 5.** In vivo effect of surfactant-associated SP-A on surfactant phospholipids hydrolysis by sPLA<sub>2</sub>-IIA. BALF were obtained 1 h after intratracheal instillation of saline or 20 μg of mGIIA sPLA<sub>2</sub>. Surfactants were then isolated and analyzed as indicated in *Materials and Methods*. **A**, Effect of mGIIA sPLA<sub>2</sub> on the ratio of PC to PG in the surfactant from SP-A<sup>+/+</sup> and SP-A<sup>-/-</sup> mice. **B**, Comparison of the amounts of surfactant PC and PG between SP-A<sup>+/+</sup> and SP-A<sup>-/-</sup> mice treated with mGIIA sPLA<sub>2</sub>, expressed as a percentage of the control value (in corresponding saline-treated mice). All results are the mean ± SEM obtained from five animals. \*,  $p < 0.007$ .

with the level of SP-A present in pulmonary surfactant (Fig. 1). Moreover, when SP-A present in surfactant from wild-type mice is neutralized with an anti-SP-A Ab, a significant increase in the release of fatty acids is observed (Fig. 2). Taken together, these data suggest that the absence of SP-A exacerbates the susceptibility of surfactant to degradation by sPLA<sub>2</sub>-IIA.

Mammalian sPLA<sub>2</sub>s are distinguished by their structural and enzymatic properties (6, 23). Subtle differences in their sequences markedly affect their substrate interfacial binding and rate of hydrolysis (32, 33). Here we analyzed the efficiencies of various sPLA<sub>2</sub>s, including recently cloned sPLA<sub>2</sub>s, to hydrolyze surfactant. Although most of these enzymes are expressed in the lung (6, 10), their enzymatic activities toward surfactant phospholipids have never been investigated. This present study shows that in addition to sPLA<sub>2</sub>-IIA, sPLA<sub>2</sub>-V and sPLA<sub>2</sub>-X are able to hydrolyze in vitro surfactant phospholipids. In these conditions PG is the most preferred substrate for sPLA<sub>2</sub>-IIA, while sPLA<sub>2</sub>-V and sPLA<sub>2</sub>-X hydrolyze PC and PG with similar rates (Fig. 3). By contrast, the other analyzed sPLA<sub>2</sub>s (IIC, IID, IIE, and IIF) are inefficient in inducing surfactant phospholipid hydrolysis.

When comparing the hydrolysis of surfactant phospholipids from SP-A<sup>-/-</sup> and SP-A<sup>+/+</sup> mice, we observed that surfactant-associated SP-A could inhibit sPLA<sub>2</sub>-IIA and sPLA<sub>2</sub>-X activities, but failed to interfere with that of sPLA<sub>2</sub>-V (Fig. 4). These findings are of great interest because it has been shown that sPLA<sub>2</sub>-IIA and



**FIGURE 6.** Effect of sPLA<sub>2</sub>-IIA instillation on respiratory function of SP-A<sup>+/+</sup> and SP-A<sup>-/-</sup> mice. mGIIA sPLA<sub>2</sub> (20 μg) or an equivalent volume of saline was administered to anesthetized mice as indicated in Fig. 5. Each animal was placed in a separate chamber of the plethysmograph, and Penh was determined as detailed in *Materials and Methods*. The figure shows the Penh increase measured 4 h after mGIIA sPLA<sub>2</sub> or saline instillation and expressed as the mean ± SEM results obtained from three animals. \*,  $p < 0.05$ .

sPLA<sub>2</sub>-X bind to the CRD domain of the M-type receptor (34–36), and a structurally similar CRD domain is also present in SP-A (37). Moreover, the binding of sPLA<sub>2</sub> to this receptor leads to an inhibition of catalytic activity (38). Surfactant-associated SP-A may therefore act as an endogenous inhibitor of sPLA<sub>2</sub>-IIA and sPLA<sub>2</sub>-X by interacting with these sPLA<sub>2</sub>s through its CRD domain.

Our results may have important pathophysiological relevance, as patients with ARDS have elevated sPLA<sub>2</sub> activity and decreased SP-A concentrations in their BALF (17–19). However, no direct causal relationship has been demonstrated between the alteration in SP-A levels and the acute destruction of surfactant phospholipids. This led us to investigate the physiological consequence of the inhibition of sPLA<sub>2</sub>-IIA activity by surfactant-associated SP-A under in vivo conditions. We first checked whether mouse sPLA<sub>2</sub>-IIA was able to hydrolyze surfactant phospholipids under in vivo conditions in mice. Several studies have shown that intratracheal administration of sPLA<sub>2</sub>s can induce lung injury with interstitial and alveolar edema, accumulation of inflammatory cells, and free fatty acid release (14, 39, 40), which are pathological features typical of those seen in the lungs of ARDS patients. However, these studies have often used heterologous sPLA<sub>2</sub>s from snake venoms, which have much higher ability than mammalian sPLA<sub>2</sub>s to hydrolyze phospholipids on packed monolayer structures. Moreover, none of these studies used mice as an animal model. In the present study no hydrolysis of surfactant PC was observed in sPLA<sub>2</sub>-IIA-treated mice. This is not surprising, since sPLA<sub>2</sub>-IIA, which bears basic residues resulting in positive charges of its interfacial binding surface, cannot bind well to PC vesicles, as described for PG (33, 41, 42).

In contrast to PC, we observed a marked decrease in surfactant PG, particularly in sPLA<sub>2</sub>-IIA-treated SP-A<sup>-/-</sup> mice. This finding is consistent with findings that sPLA<sub>2</sub>-IIA is >100-fold more active on anionic, rather than zwitterionic, phospholipids (9, 30). Remarkably, hydrolysis of PG occurs as early as 1 h after sPLA<sub>2</sub>-IIA administration, indicating that this enzyme could account for surfactant abnormalities observed at early phases in ARDS (17). In fact, alterations in the relative composition of the surfactant phospholipids

are seen in patients with ARDS (17, 18, 43, 44). A decrease in PG levels (by >80% in three of these studies) and a moderate reduction of PC levels were observed. Taken together, these data support a role for sPLA<sub>2</sub>-IIA in the alterations in PG levels occurring during the early phase of ARDS.

Therefore, it should be of great interest to know whether PG hydrolysis contributes to the pathophysiological events encountered in ARDS. Surfactant from sPLA<sub>2</sub>-IIA-treated SP-A<sup>-/-</sup> mice showed an increase in the PC/PG ratio (Fig. 5A). Interestingly, Hite et al. (45) observed PG hydrolysis by sPLA<sub>2</sub> in asthmatic patients. They demonstrated a positive correlation between the PC/PG ratio and surfactant dysfunction, and they concluded that the hydrolysis of surfactant PG by sPLA<sub>2</sub> may be a mechanism contributing to surfactant dysfunction. Moreover, we showed here that intratracheal administration of mouse sPLA<sub>2</sub>-IIA leads to a time-dependent increase in Penh, demonstrating that the enzyme has a deleterious effect on lung function (Fig. 6). In this study we did not demonstrate a direct relationship between the decrease in PG content and the impairment of lung function. However, as PG has a relatively high content of unsaturated fatty acids, it may be functionally important because of its capacity to increase monolayer film fluidity and adsorption (46). It has also been shown that PG prevents the collapse of the surfactant film (47). Thus, surfactant PG hydrolysis by sPLA<sub>2</sub>-IIA may contribute to surfactant dysfunction. The pathophysiological relevance of these results is linked to the fact that the surface activity of the surfactant film from patients with ARDS is abnormal, including a reduced rate of absorption, higher surface compressibility, and lower film stability index (17, 48).

Surfactant PG from SP-A<sup>-/-</sup> mice was significantly more susceptible to hydrolysis by sPLA<sub>2</sub>-IIA compared with that from wild-type mice (Fig. 5B). This pronounced susceptibility was not due to differences in surfactant composition, since mice lacking SP-A produce similar levels of surfactant phospholipids and of other surfactant proteins compared with wild-type mice (20). We also observed that the increase in Penh resulting from sPLA<sub>2</sub>-IIA administration was higher in SP-A<sup>-/-</sup> mice compared with wild-type mice. Taken together, these data strongly suggest that SP-A is an efficient endogenous inhibitor of sPLA<sub>2</sub>-IIA enzymatic activity and thereby plays a protective role in maintaining pulmonary surfactant integrity during lung injury. Whether endogenous SP-A can also protect surfactant from hydrolysis by other sPLA<sub>2</sub>s that might be overexpressed during mouse acute lung injury remains to be determined.

This report also demonstrates a deleterious effect of sPLA<sub>2</sub>-IIA, sPLA<sub>2</sub>-V, and sPLA<sub>2</sub>-X on pulmonary surfactant, suggesting a possible involvement of these enzymes in the pathogenesis of ARDS. Our findings support a potential role for SP-A in the protection of surfactant in the early phases of ARDS. Our results corroborate the view that surfactant replacement therapy for ARDS might be enhanced by addition of SP-A.

## Acknowledgments

We gratefully acknowledge Dr. F. X. McCormack for providing us the rabbit polyclonal anti-SP-A Ab, and C. Le Calvez for technical assistance. We are also very grateful to J. Lefort for his excellent technical assistance with measurements of Penh.

## References

- Ware, L. B., and M. A. Matthay. 2000. The acute respiratory distress syndrome. *N. Engl. J. Med.* 342:1334.
- Dobbs, L. G. 1989. Pulmonary surfactant. *Annu. Rev. Med.* 40:431.
- Holm, B. A., L. Keicher, M. Y. Liu, J. Sokolowski, and G. Enhorning. 1991. Inhibition of pulmonary surfactant function by phospholipases. *J. Appl. Physiol.* 71:317.

4. Touqui, L., and L. Arbibe. 1999. A role for phospholipase A<sub>2</sub> in ARDS pathogenesis. *Mol. Med. Today* 5:244.
5. Six, D. A., and E. A. Dennis. 2000. The expanding superfamily of phospholipase A<sub>2</sub> enzymes: classification and characterization. *Biochim. Biophys. Acta* 1488:1.
6. Valentin, E., and G. Lambeau. 2000. Increasing molecular diversity of secreted phospholipases A<sub>2</sub> and their receptors and binding proteins. *Biochim. Biophys. Acta* 1488:59.
7. Murakami, M., and I. Kudo. 2002. Phospholipase A<sub>2</sub>. *J. Biochem.* 131:285.
8. Valentin, E., F. Ghomashchi, M. H. Gelb, M. Lazdunski, and G. Lambeau. 2000. Novel human secreted phospholipase A<sub>2</sub> with homology to the group III bee venom enzyme. *J. Biol. Chem.* 275:7492.
9. Valentin, E., R. S. Koduri, J. C. Scimeca, G. Carle, M. H. Gelb, M. Lazdunski, and G. Lambeau. 1999. Cloning and recombinant expression of a novel mouse-secreted phospholipase A<sub>2</sub>. *J. Biol. Chem.* 274:19152.
10. Valentin, E., F. Ghomashchi, M. H. Gelb, M. Lazdunski, and G. Lambeau. 1999. On the diversity of secreted phospholipases A<sub>2</sub>: cloning, tissue distribution, and functional expression of two novel mouse group II enzymes. *J. Biol. Chem.* 274:31195.
11. Cupillard, L., K. Koumanov, M. G. Mattei, M. Lazdunski, and G. Lambeau. 1997. Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A<sub>2</sub>. *J. Biol. Chem.* 272:15745.
12. Gelb, M. H., E. Valentin, F. Ghomashchi, M. Lazdunski, and G. Lambeau. 2000. Cloning and recombinant expression of a structurally novel human secreted phospholipase A<sub>2</sub>. *J. Biol. Chem.* 275:39823.
13. Kim, D. K., T. Fukuda, B. T. Thompson, B. Cockrill, C. Hales, and J. V. Bonventre. 1995. Bronchoalveolar lavage fluid phospholipase A<sub>2</sub> activities are increased in human adult respiratory distress syndrome. *Am. J. Physiol.* 269:L109.
14. Arbibe, L., K. Koumanov, D. Vial, C. Rougeot, G. Faure, N. Havet, S. Longacre, B. B. Vargaftig, G. Berezziat, D. R. Voelker, et al. 1998. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A<sub>2</sub> and inhibited by a direct surfactant protein A-phospholipase A<sub>2</sub> protein interaction. *J. Clin. Invest.* 102:1152.
15. Baker, C. S., T. W. Evans, B. J. Randle, and P. L. Haslam. 1999. Damage to surfactant-specific protein in acute respiratory distress syndrome. *Lancet* 353:1232.
16. Kuroki, Y., and D. R. Voelker. 1994. Pulmonary surfactant proteins. *J. Biol. Chem.* 269:25943.
17. Gregory, T. J., W. J. Longmore, M. A. Moxley, J. A. Whitsett, C. R. Reed, A. A. Fowler III, L. D. Hudson, R. J. Maunder, C. Crim, and T. M. Hyers. 1991. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. *J. Clin. Invest.* 88:1976.
18. Gunther, A., C. Siebert, R. Schmidt, S. Ziegler, F. Grimminger, M. Yabut, B. Temmesfeld, D. Walmrath, H. Morr, and W. Seeger. 1996. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. *Am. J. Respir. Crit. Care Med.* 153:176.
19. Veldhuizen, R. A., L. A. McCaig, T. Akino, and J. F. Lewis. 1995. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. *Am. J. Respir. Crit. Care Med.* 152:1867.
20. Korfhagen, T. R., M. D. Bruno, G. F. Ross, K. M. Huelsman, M. Ikegami, A. H. Jobe, S. E. Wert, B. R. Stripp, R. E. Morris, S. W. Glasser, et al. 1996. Altered surfactant function and structure in SP-A gene targeted mice. *Proc. Natl. Acad. Sci. USA* 93:9594.
21. Dranoff, G., A. D. Crawford, M. Sadelain, B. Ream, A. Rashid, R. T. Bronson, G. R. Dickersin, C. J. Bachurski, E. L. Mark, J. A. Whitsett, et al. 1994. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. *Science* 264:713.
22. Vial, D., M. Senorale-Pose, N. Havet, L. Molio, B. B. Vargaftig, and L. Touqui. 1995. Expression of the type-II phospholipase A<sub>2</sub> in alveolar macrophages: down-regulation by an inflammatory signal. *J. Biol. Chem.* 270:17327.
23. Singer, A. G., F. Ghomashchi, C. Le Calvez, J. Bollinger, S. Bezzine, M. Rouault, M. Sadilek, E. Nguyen, M. Lazdunski, G. Lambeau, et al. 2002. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A<sub>2</sub>. *J. Biol. Chem.* 277:48535.
24. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680.
25. Tsujishita, Y., Y. Asaoka, and Y. Nishizuka. 1994. Regulation of phospholipase A<sub>2</sub> in human leukemia cell lines: its implication for intracellular signaling. *Proc. Natl. Acad. Sci. USA* 91:6274.
26. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* 37:911.
27. Böttcher, C. J. F., C. M. van Gent, and C. Pries. 1961. A rapid and sensitive sub-microphosphorus determination. *Anal. Clin. Acta.* 24:203.
28. Huffman, J. A., W. M. Hull, G. Dranoff, R. C. Mulligan, and J. A. Whitsett. 1996. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. *J. Clin. Invest.* 97:649.
29. Ikegami, M., T. R. Korfhagen, J. A. Whitsett, M. D. Bruno, S. E. Wert, K. Wada, and A. H. Jobe. 1998. Characteristics of surfactant from SP-A-deficient mice. *Am. J. Physiol.* 275:L247.
30. Snitko, Y., E. T. Yoon, and W. Cho. 1997. High specificity of human secretory class II phospholipase A<sub>2</sub> for phosphatidic acid. *Biochem. J.* 321:737.
31. Dennis, E. A. 1978. Mechanism of phospholipase A<sub>2</sub> action toward mixed micelles of detergent and phospholipids. *Adv. Exp. Med. Biol.* 101:165.
32. Waite, M. 1990. Phospholipases, enzymes that share a substrate class. *Adv. Exp. Med. Biol.* 279:1.
33. Berg, O. G., M. H. Gelb, M. D. Tsai, and M. K. Jain. 2001. Interfacial enzymology: the secreted phospholipase A<sub>2</sub>-paradigm. *Chem. Rev.* 101:2613.
34. Cupillard, L., R. Mulherkar, N. Gomez, S. Kadam, E. Valentin, M. Lazdunski, and G. Lambeau. 1999. Both group IB and group IIA secreted phospholipases A<sub>2</sub> are natural ligands of the mouse 180-kDa M-type receptor. *J. Biol. Chem.* 274:7043.
35. Nicolas, J. P., G. Lambeau, and M. Lazdunski. 1995. Identification of the binding domain for secretory phospholipases A<sub>2</sub> on their M-type 180-kDa membrane receptor. *J. Biol. Chem.* 270:28869.
36. Yokota, Y., K. Higashino, K. Nakano, H. Arita, and K. Hanasaki. 2000. Identification of group X secretory phospholipase A<sub>2</sub> as a natural ligand for mouse phospholipase A<sub>2</sub> receptor. *FEBS Lett.* 478:187.
37. Haagsman, H. P., S. Hawgood, T. Sargeant, D. Buckley, R. T. White, K. Drickamer, and B. J. Benson. 1987. The major lung surfactant protein, SP 28-36, is a calcium-dependent, carbohydrate-binding protein. *J. Biol. Chem.* 262:13877.
38. Ancian, P., G. Lambeau, and M. Lazdunski. 1995. Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A<sub>2</sub>. *Biochemistry* 34:13146.
39. Durham, S. K., and W. M. Selig. 1990. Phospholipase A<sub>2</sub>-induced pathophysiological changes in the guinea pig lung. *Am. J. Pathol.* 136:1283.
40. Edelson, J. D., P. Vadas, J. Villar, J. B. Mullen, and W. Pruzanski. 1991. Acute lung injury induced by phospholipase A<sub>2</sub>: structural and functional changes. *Am. Rev. Respir. Dis.* 143:1102.
41. Bezzine, S., R. S. Koduri, E. Valentin, M. Murakami, I. Kudo, F. Ghomashchi, M. Sadilek, G. Lambeau, and M. H. Gelb. 2000. Exogenously added human group X secreted phospholipase A<sub>2</sub> but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. *J. Biol. Chem.* 275:3179.
42. Gadd, M. E., and R. L. Biltonen. 2000. Characterization of the interaction of phospholipase A<sub>2</sub> with phosphatidylcholine-phosphatidylglycerol mixed lipids. *Biochemistry* 39:9623.
43. Hallman, M., R. Spragg, J. H. Harrell, K. M. Moser, and L. Gluck. 1982. Evidence of lung surfactant abnormality in respiratory failure: study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. *J. Clin. Invest.* 70:673.
44. Pison, U., W. Seeger, R. Buchhorn, T. Joka, M. Brand, U. Obertacke, H. Neuhoef, and K. P. Schmit-Neuerburg. 1989. Surfactant abnormalities in patients with respiratory failure after multiple trauma. *Am. Rev. Respir. Dis.* 140:1033.
45. Hite, R. D., D. L. Bowtoon, M. C. Seeds, A. M. Safta, B. M. Waite, and D. A. Bass. 2001. Phospholipase A<sub>2</sub>-mediated phosphatidylglycerol deficiency predicts surfactant dysfunction in asthma. *Am. J. Respir. Crit. Care Med.* 163:733a (Abstr.).
46. Jacob, J., M. Hallman, and L. Gluck. 1980. Phosphatidylinositol and phosphatidylglycerol enhance surface active properties of lecithin. *Pediatr. Res.* 14:644a (Abstr.).
47. Bangham, A. D., C. J. Moley, and M. C. Phillips. 1979. The physical properties of an effective lung surfactant. *Biochim. Biophys. Acta.* 573:552.
48. Lewis, J. F., M. Ikegami, A. H. Jobe, and D. Absalom. 1993. Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuniform pattern of lung injury. *Am. Rev. Respir. Dis.* 147:1364.